Form 4: Acadia Pharmaceuticals Officer James Kihara Reports Stock Transactions

James Kihara, Principal Accounting Officer of Acadia Pharmaceuticals, reports the vesting and sale of restricted stock units to cover tax obligations.

Summary

• James Kihara, the Principal Accounting Officer of Acadia Pharmaceuticals, filed a Form 4 detailing changes in beneficial ownership.
• On April 5, 2025, 2,010 restricted stock units vested and were converted into common stock.
• Also on April 5, 2025, 2,010 shares of common stock were disposed of.
• On April 8, 2025, 1,028 shares were sold at a price of $14.82 per share to cover withholding taxes related to the vesting of the restricted stock units.
• Following these transactions, Kihara directly owns 22,257 shares of Acadia Pharmaceuticals common stock.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing detailing stock transactions by a company officer. It doesn't inherently convey positive or negative sentiment, as it simply reports factual information.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This filing indicates the vesting of stock options and subsequent sale to cover tax obligations, a common practice.

Comparison to Industry Standards

• Stock sales to cover tax obligations upon vesting of restricted stock units are a standard practice across publicly traded companies.
• The sale price of $14.82 per share can be compared to the average trading price of Acadia Pharmaceuticals stock on April 8, 2025, to assess whether the sale was executed at a fair market value.

Stakeholder Impact

• The transactions reported in the Form 4 have a minimal direct impact on stakeholders, as they represent routine stock sales by an officer to cover tax obligations.

Key Dates

Keywords

Form 4, Beneficial Ownership, Stock Sale, Restricted Stock Units, Acadia Pharmaceuticals, Kihara, Officer